Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jun 12.
doi: 10.1002/mdc3.70175. Online ahead of print.

ADCY5-Mosaic Variants: A Diagnosis Not to Be Missed

Affiliations
Case Reports

ADCY5-Mosaic Variants: A Diagnosis Not to Be Missed

Alice Innocenti et al. Mov Disord Clin Pract. .

Abstract

Background: An increasing number of ADCY5-mosaic patients, seemingly with a milder phenotype, are being identified. However, an in-depth assessment of their clinical characteristics is lacking.

Cases: We collected and analyzed data from 12 consecutive ADCY5-mosaic patients diagnosed at our center and 7 cases from the literature; 63% of the patients presented with a baseline hyperkinetic motor disorder with paroxysmal motor exacerbations; 30% had isolated paroxysmal dyskinesias (PxD). Caffeine treatment was highly effective. Developmental delay was observed in 5 patients and especially in those with persistent motor symptoms. PxD were the initial motor symptom in 70% of cases.

Conclusions: ADCY5-mosaic carriers may have the same phenotypic spectrum as non-mosaic carriers but with a milder clinical presentation. Isolated PxD with onset in infancy are a red flag for ADCY5-mosaic variants. Particular attention should be paid when genetic analysis of patients with this phenotype is conducted as mosaicism can be easily missed.

Keywords: ADCY5‐mosaic; mixed movement disorder ADCY5 (MxMD‐ADCY5); paroxysmal dyskinesias (PxD).

PubMed Disclaimer

References

    1. Friedman JR, Méneret A, Chen D‐H, Trouillard O, Vidailhet M, Raskind WH, Roze E. ADCY5 mutation carriers display pleiotropic paroxysmal day and nighttime dyskinesias. Mov Disord 2016;31:147–148.
    1. Delorme C, Giron C, Bendetowicz D, Méneret A, Mariani L‐L, Roze E. Current challenges in the pathophysiology, diagnosis, and treatment of paroxysmal movement disorders. Expert Rev Neurother 2021;21:81–97.
    1. Menon PJ, Nilles C, Silveira‐Moriyama L, et al. Scoping review on ADCY5‐related movement disorders. Mov Disord Clin Pract 2023;10:1048–1059.
    1. Chen D‐H, Méneret A, Friedman JR, et al. ADCY5‐related dyskinesia: broader spectrum and genotype‐phenotype correlations. Neurology 2015;85:2026–2035.
    1. Méneret A, Mohammad SS, Cif L, et al. Efficacy of caffeine in ADCY5‐related dyskinesia: a retrospective study. Mov Disord 2022;37:1294–1298.

Publication types

Grants and funding

LinkOut - more resources